An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.
The VC firm has invested in at least five startups, according to public disclosures. That includes bone disorder biotech āshibio; epigenetics company Moonwalk Biosciences, which was co-founded by Feng Zhang; synthetic biology startup Think Bioscience; regenerative medicine-focused Tempo Therapeutics; and hair loss drug developer Pelage Pharmaceuticals.
Gary Yeung and Mitchell Kossar are leading the Burlingame, CA-based firm. Yeung previously held executive roles at GGTG Biosciences, xilis, and Erasca, and spent a dozen years at Genentech, which he departed in 2016. Meanwhile, Kossar is president of a life sciences consultancy called First Principles Advisory Group, according to his LinkedIn profile.
On his LinkedIn profile, Yeung describes YK as “Beyond Capital,” meaning it provides…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
